JANSSEN BIOTECH, INC. Patent applications |
Patent application number | Title | Published |
20160040130 | DIFFERENTIATION OF PLURIPOTENT STEM CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method utilizing a CYP26A inhibitor to produce a population of pancreatic endocrine precursor cells. | 02-11-2016 |
20160032250 | Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon. | 02-04-2016 |
20160030480 | Cellular Therapy for Ocular Degeneration - Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45. | 02-04-2016 |
20150353895 | Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells. | 12-10-2015 |
20150329828 | Use of Small Molecules to Enhance Mafa Expression in Pancreatic Endocrine Cells - The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells of a mature phenotype. The resulting pancreatic endocrine cells express single hormonal insulin, PDX1, NKX6.1, and MAFA. In one or more differentiation stages, culturing may be carried out in a culture vessel at the air-liquid interface. | 11-19-2015 |
20150307600 | ANTI-PHF-TAU ANTIBODIES AND THEIR USES - Anti-PHF-tau antibodies and methods of making and using them are disclosed. | 10-29-2015 |
20150191700 | Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides a method to increase the expression of markers associated with the pancreatic endocrine lineage. | 07-09-2015 |
20150087812 | Human Autotaxin Antibodies and Methods of Use - Antibodies and compositions capable of binding and, in a particular aspect, inhibiting the lysophosphatidylipase D activity of human autotaxin protein. The antibodies or are useful in detecting human autotaxin protein and treating diseases and disorders associated with unwanted lysophosphatidylipase D and the presence of lysophosphatidic acid, such as cancer and pulmonary diseases. | 03-26-2015 |
20140273092 | MANUFACTURING METHODS TO CONTROL C-TERMINAL LYSINE, GALACTOSE AND SIALIC ACID CONTENT IN RECOMBINANT PROTEINS - Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody. | 09-18-2014 |
20140271648 | Interferon Alpha and Omega Antibody Antagonists - Broadly neutralizing interferon-α and interferon-ω antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFNα and IFNω. | 09-18-2014 |
20140261706 | Media Suction Devices and Methods - Devices and methods are provided for removing media from a culture vessel that decreases disruption of the interface between the cellular material and media within the vessel such that aspiration and removal of cells or cell clusters along with the media is minimized. In addition, the media fluid turbulence is decreased so as to minimize the activation or disruption of cells and cell clusters. | 09-18-2014 |
20140255408 | Bispecific EGFR/C-Met Antibodies - Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. | 09-11-2014 |
20140255401 | Kv1.3 Antagonists and Methods of Use - The present invention relates to Kv1.3 antagonists, and polynucleotides encoding them, and methods of making and using the foregoing. | 09-11-2014 |
20140242693 | Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells - The present invention provides methods of preparing aggregated pluripotent stem cell clusters for differentiation. | 08-28-2014 |
20140234304 | HUMAN TISSUE FACTOR ANTIBODY AND USES THEREOF - The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs. | 08-21-2014 |
20140220634 | Antibodies binding human collagen II - The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing. | 08-07-2014 |
20140212426 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 07-31-2014 |
20140212413 | Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 07-31-2014 |
20140206599 | IL4/IL13 Binding Repeat Proteins and Uses - IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions. | 07-24-2014 |
20140186953 | Differentiation of Human Embryonic Stem Cells Into Pancreatic Endocrine Cells Using HB9 Regulators - The present invention provides methods to promote differentiation of pluripotent stem cells to pancreatic endoderm cells expressing PDX1, NKX6.1, and HB9. In particular, the methods encompass culturing Stage 4 to Stage 6 cells with a thyroid hormone (e.g. T3), an ALK5 inhibitor, or both. | 07-03-2014 |
20140186305 | Culturing of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine Cells - The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells expressing PDX1, NKX6.1, and HB9 by culturing in a culture vessel at the air-liquid interface. The invention also provides for in vivo maturation of cells cultured at the air-liquid interface. | 07-03-2014 |
20140178295 | Method for Treating Psoriasis By Administering An Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriasis. | 06-26-2014 |
20140162359 | Differentiation of Human Embryonic Stem Cells into Pancreatic Endoderm - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of pancreatic endoderm cells, wherein the initial seeding density of undifferentiated epluripotent cells is defined. | 06-12-2014 |
20140162316 | Anti-GLP-1R Antibodies and Their Uses - The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them. | 06-12-2014 |
20140155326 | EGFR AND C-MET FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES - Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 06-05-2014 |
20140155325 | EGFR AND C-MET FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES - Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 06-05-2014 |
20140141506 | Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 05-22-2014 |
20140141459 | PENTRAXIN 3 ASSOCIATION WITH ASTHMA - The present invention relates to methods of utilizing pentraxin 3 as a marker for therapeutic efficacy in preclinical models of asthma. | 05-22-2014 |
20140141013 | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 05-22-2014 |
20140141000 | Bispecific EGFR/C-Met Antibodies - Bispecific EGFR/c-Met antibodies and methods of making and using the molecules. | 05-22-2014 |
20140128576 | Anti-IL-23 Antibodies, Compositions, Methods and Uses - An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 05-08-2014 |
20140099311 | Anti-IL-6 Antibodies, Compositions, Methods and Uses - An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 04-10-2014 |
20140093523 | Anti-Integrin Immunoconjugates, Methods and Uses - The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog. | 04-03-2014 |
20140093508 | Toll-Like 3 Receptor Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 04-03-2014 |
20140080210 | Treatment of Pluripotent Cells - The present invention is directed to methods to treat pluripotent cells, whereby the pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of GSK-3B enzyme activity. | 03-20-2014 |
20140079711 | ANTI-CD147 ANTIBODIES, METHODS AND USES - The present invention provides antibodies immunospecific for human CD147 capable of blocking bioactivity of CD147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system. | 03-20-2014 |
20140046031 | Anti-IL-23 Antibodies, Compositions, Methods and Uses - An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 02-13-2014 |
20140018519 | Stabilized Fibronectin Domain Compositions, Methods and Uses - A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices. | 01-16-2014 |
20140017250 | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 01-16-2014 |
20140011879 | SERUM MARKERS FOR IDENTIFICATION OF CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS - Tools for diagnosis and management of patients suspected of having or having been previously diagnosed with systemic sclerosis are based on the determination one or more of the markers described herein, specifically, the markers having the amino acid sequence of SEQ ID NOS: 1-62 and 66-76 in a sample from the subject. Specific marker ratios and subsets of markers and ratios identify a patient and further subclassify the patient. The information may be used prospectively to study the response of subclassified patients to existing or novel therapeutic strategies. | 01-09-2014 |
20140011704 | Markers and Methods for Assessing and Treating Crohn's Disease and Related Disorders - A method for assessment of the suitability of and/or effectiveness of a target therapy for a gastrointestinal-related disorder, such as Crohn's disease, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 10-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to or after starting a patient on such therapies. | 01-09-2014 |
20130336980 | ST2L Antagonists and Methods of Use - The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. | 12-19-2013 |
20130316952 | Non-Natural Consensus Albumin Binding Domains - Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients. | 11-28-2013 |
20130316923 | METHODS FOR PREDICTING ANTI-INTEGRIN ANTIBODY RESPONSE - The present invention relates to methods and procedures for predicting responsiveness to anti-integrin αv monoclonal antibody. | 11-28-2013 |
20130310324 | HUWENTOXIN-IV VARIANTS AND METHODS OF USE - The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, and methods of making and using the foregoing. | 11-21-2013 |
20130295084 | BINDING PROTEINS HAVING TETHERED LIGHT CHAINS - The present invention relates to binding proteins having tethered light chains and methods of making and using them. | 11-07-2013 |
20130287777 | ST2L Antagonists and Methods of Use - The present invention relates to ST2L antagonists, polynucleotides encoding the antagonists or fragments thereof, and methods of making and using the foregoing. | 10-31-2013 |
20130280263 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 10-24-2013 |
20130244281 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 09-19-2013 |
20130243795 | HUMAN ANTI-CD27 ANTIBODIES, METHODS AND USES - Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions. | 09-19-2013 |
20130239238 | Immunoglobulin Cleavage Fragments and Disease Indicators and Compositions for Detecting and Binding Such - The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG protease cleavage products to restore effector function to antibody compositions that are subject to protease cleavage. | 09-12-2013 |
20130236973 | Defined Media for Expansion and Maintenance of Pluripotent Stem Cells - The present invention provides methods to promote the proliferation of undifferentiated pluripotent stem cells in defined media. Specifically, the invention provides a defined cell culture formulation for the culture, maintenance, and expansion of pluripotent stem cells, wherein culturing stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages. Further disclosed is a cell population grown under defined media conditions that express OCT4, SOX2, NANOG, and FOXA2. | 09-12-2013 |
20130189777 | Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides methods to produce a population of cells, wherein greater than 10% of the cells in the population express markers characteristic of single hormonal pancreatic beta cells. | 07-25-2013 |
20130189250 | Human Tissue Factor Antibody and Uses Thereof - The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs. | 07-25-2013 |
20130183298 | Methods of Treating Hepatitis With Anti-TNF alpha Antibodies - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 07-18-2013 |
20130171136 | Methods of Treating Giant Cell Arteritis With Anti-TNF Alpha Antibodies - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 07-04-2013 |
20130129617 | Method for Treating Psoriatic Arthritis By Administering An Anti-IL-12 Antibody - An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriatic arthritis. | 05-23-2013 |
20130090457 | Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 04-11-2013 |
20130079243 | Fibronectin Type III Repeat Based Protein Scaffolds with Alternative Binding Surfaces - Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 03-28-2013 |
20130064760 | Method for Treating Crohn's Disease By Administering An Anti-IL-12 Antibody - Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as Crohn's disease. | 03-14-2013 |
20120039955 | Treatment of Diabetes with Pancreatic Endocrine Precursor Cells - The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal. | 02-16-2012 |